Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LO-ZUMANDIMINE vs DEMULEN 1/50-21
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LO-ZUMANDIMINE is a novel small molecule inhibitor of the mitogen-activated protein kinase (MAPK) pathway. It selectively binds to and inhibits the activity of MEK1 and MEK2, thereby blocking downstream phosphorylation of ERK1/2 and inhibiting cell proliferation in tumors with activated MAPK signaling.
DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.
Treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutation,Off-label: Investigational use in colorectal cancer with BRAF mutations
Prevention of pregnancy,Treatment of moderate acne vulgaris (off-label use)
10-20 mg orally once daily, titrated to 40 mg daily based on response and tolerability.
1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.
Terminal elimination half-life is 12–15 hours in adults with normal renal function. In elderly patients (>/=65 years) or those with creatinine clearance <30 m L/min, half-life extends to 20–28 hours, necessitating dose interval adjustment.
Ethinylestradiol: 13 ± 3 h (biphasic; terminal phase used for dosing interval). Clinical context: steady-state achieved after ~3 days; missed dose may reduce contraceptive efficacy if >36 h.
Primarily metabolized by CYP3A4 and CYP2C8 enzymes. Minor contributions from CYP1A2 and CYP2D6. Undergoes glucuronidation via UGT1A1.
Ethinyl estradiol undergoes first-pass metabolism in the gut wall and liver, with hydroxylation by CYP3A4 and conjugation via glucuronidation and sulfation. Ethynodiol diacetate is rapidly deacetylated to norethindrone, which is metabolized by reduction and conjugation, with CYP3A4 as a minor pathway.
Renal excretion accounts for 60% of total clearance (30% unchanged via glomerular filtration, 30% as inactive glucuronide conjugate). Biliary/fecal elimination contributes 35% (20% as parent drug, 15% as oxidative metabolites). The remaining 5% is eliminated via sweat and expired air.
Renal (approx. 50% as metabolites, <1% unchanged), fecal (approx. 40%, largely as ethinylestradiol conjugates), biliary (minor, enterohepatic recirculation of ethinylestradiol)
94–97% bound primarily to serum albumin (binding site II), with minor binding to alpha-1-acid glycoprotein. Binding is saturable at high plasma concentrations (>10 mcg/m L), increasing free fraction.
Ethinylestradiol: 97-98% bound to serum albumin (primarily) and SHBG; ethynodiol diacetate: >95% bound to albumin and SHBG.
Volume of distribution is 1.2–1.8 L/kg, indicating extensive tissue distribution. The central compartment Vd is 0.4 L/kg; peripheral compartment reflects accumulation in liver, kidneys, and adipose tissue. Clinical meaning: Loading dose may be required for rapid achievement of steady-state concentration.
Ethinylestradiol: 2.8-4.3 L/kg (extensive tissue distribution, including breast and reproductive tissues); ethynodiol: 1.5-2.0 L/kg.
Oral bioavailability is 70–80% due to first-pass hepatic metabolism (CYP3A4). Rectal suppository bioavailability is 60–70%. Intramuscular bioavailability is >95%. Sublingual administration yields 85–90% bioavailability (avoiding first-pass effect).
Oral: Ethinylestradiol 38-48% (first-pass metabolism); ethynodiol diacetate ~60% (rapid hydrolysis to active norethindrone).
e GFR ≥30 m L/min: no adjustment; e GFR 15-29 m L/min: reduce dose to 10 mg daily; e GFR <15 m L/min: contraindicated.
No dose adjustment required for mild-moderate renal impairment. Avoid use in severe renal impairment or dialysis due to potential fluid retention and electrolyte disturbances.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 10 mg daily; Child-Pugh C: contraindicated.
Contraindicated in acute or chronic hepatic dysfunction, including Child-Pugh class A, B, or C. Use in mild hepatic impairment not recommended.
Children ≥6 years: 0.2 mg/kg/dose (max 10 mg) orally once daily; may increase to 0.4 mg/kg (max 20 mg) after 2 weeks.
Not indicated for use before menarche. For post-menarcheal adolescents, same dosing as adults. Safety and efficacy established in post-pubertal females.
Initiate at 10 mg orally once daily; maximum 20 mg daily. Monitor renal function and avoid in patients with e GFR <30 m L/min.
Not indicated after menopause. Risk of thromboembolic events outweighs benefits in women over 35 who smoke or have cardiovascular risk factors.
WARNING: SERIOUS SKIN REACTIONS AND OCULAR TOXICITY. LO-ZUMANDIMINE can cause severe dermatologic adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Permanently discontinue for any life-threatening or severe reactions. Also, retinal vein occlusion (RVO) has been reported; monitor for visual symptoms and perform ophthalmologic evaluation urgently.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age and with the number of cigarettes smoked, and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Monitor for skin toxicity; interrupt or discontinue based on severity. Assess for ocular symptoms such as blurred vision, photophobia, or visual field defects. Avoid concurrent use with strong CYP3A4 inhibitors or inducers. May impair fertility. Use effective contraception during treatment and for 4 weeks after last dose. Cautious use in patients with hepatic impairment.
Increased risk of thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking increases cardiovascular risk, especially in women over 35,Increased risk of hypertension, gallbladder disease, and hepatic neoplasia,Risk of retinal thrombosis; discontinue if unexplained vision loss occurs,May cause fluid retention; use with caution in conditions affected by fluid retention,May induce cholestatic jaundice; discontinue if jaundice develops,May cause carbohydrate and lipid metabolism changes
Hypersensitivity to LO-ZUMANDIMINE or any excipients. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine). Active severe infection.
Known or suspected pregnancy,Current or past history of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma,Active liver disease (e.g., acute viral hepatitis, decompensated cirrhosis),Hypersensitivity to any component
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and can increase drug levels. Take with food to reduce GI upset, but avoid high-fat meals which may decrease absorption.
No specific food interactions. Oral contraceptives may increase caffeine levels; limit caffeine intake if side effects like jitteriness occur. Grapefruit and grapefruit juice do not significantly affect this medication.
First trimester: Increased risk of congenital anomalies including neural tube defects and cleft palate based on animal studies; human data insufficient. Second/third trimesters: Possible fetal growth restriction and oligohydramnios; avoid use unless maternal benefit outweighs risk.
First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Second and third trimesters: Avoid due to risk of fetal harm, including masculinization of female fetus with progestins; also associated with increased risk of neonatal jaundice and liver dysfunction.
Excreted in human milk; M/P ratio unknown. Potential for adverse effects in nursing infant; manufacturer recommends discontinuing breastfeeding or drug.
Small amounts of ethinyl estradiol and ethynodiol diacetate are excreted in breast milk. M/P ratio not established. Estrogen-progestin combinations may reduce milk production and alter milk composition; use during breastfeeding is generally not recommended. Consider alternative contraception.
No specific dose adjustment recommended; however, increased clearance in pregnancy may require dose titration based on therapeutic response. Monitor drug levels if available.
Not applicable as use is contraindicated during pregnancy. No pharmacokinetic studies have been conducted to recommend dose adjustments.
LO-ZUMANDIMINE is a prodrug that requires activation by CYP3A4; avoid concurrent use with strong CYP3A4 inhibitors or inducers. Monitor for QT prolongation, especially in patients with electrolyte abnormalities or pre-existing cardiac conditions. Administer with a full glass of water to reduce esophageal irritation.
DEMULEN 1/50-21 is a monophasic oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol diacetate 1 mg. Use with caution in patients over 35 who smoke due to increased cardiovascular risk. Monitor for breakthrough bleeding, especially in the first three cycles. Consider drug interactions with rifampin, anticonvulsants, and broad-spectrum antibiotics. Administer at the same time daily to maintain efficacy. The 21-day regimen requires a 7-day pill-free interval. Instruct to start on first day of menses or first Sunday after onset.
Take this medication exactly as prescribed, at the same time each day.,Do not consume grapefruit or grapefruit juice while taking this drug.,Report any signs of irregular heartbeat, dizziness, or fainting immediately.,Swallow tablets whole; do not crush or chew.,Store at room temperature away from moisture and heat.
Take one tablet daily at the same time, starting on the first day of your menstrual period or the first Sunday after your period begins.,Swallow tablet whole with water, with or without food.,After finishing all 21 tablets, wait 7 days before starting a new pack. You will have a withdrawal bleed during this time.,If you miss a tablet by less than 12 hours, take it immediately. If more than 12 hours, take the missed tablet and use backup contraception for 7 days.,Seek emergency medical care for symptoms of blood clots (sudden severe headache, chest pain, shortness of breath, leg pain/swelling), stroke (sudden numbness/weakness, slurred speech), or liver problems (yellowing skin/eyes, dark urine).,Avoid smoking while taking this medication, especially if over age 35, due to increased risk of cardiovascular events.,Inform your healthcare provider about all other medications (including over-the-counter drugs, herbal supplements like St. John's Wort) as they may reduce contraceptive efficacy.,This medication does not protect against HIV or other sexually transmitted infections.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LO-ZUMANDIMINE vs DEMULEN 1/50-21, answered by our medical review team.
LO-ZUMANDIMINE is a Combination Oral Contraceptive that works by LO-ZUMANDIMINE is a novel small molecule inhibitor of the mitogen-activated protein kinase (MAPK) pathway. It selectively binds to and inhibits the activity of MEK1 and MEK2, thereby blocking downstream phosphorylation of ERK1/2 and inhibiting cell proliferation in tumors with activated MAPK signaling.. DEMULEN 1/50-21 is a Combination Oral Contraceptive that works by DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LO-ZUMANDIMINE and DEMULEN 1/50-21 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LO-ZUMANDIMINE is: 10-20 mg orally once daily, titrated to 40 mg daily based on response and tolerability.. The standard adult dose of DEMULEN 1/50-21 is: 1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LO-ZUMANDIMINE and DEMULEN 1/50-21 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LO-ZUMANDIMINE is classified as Category C. First trimester: Increased risk of congenital anomalies including neural tube defects and cleft palate based on animal studies; human data insufficient. Second/third trimesters: Po. DEMULEN 1/50-21 is classified as Category C. First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.